• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Rheumatoid arthritis (RA) - Articles and news items

rheumatoid-arthritis

Janssen submits EU application for rheumatoid arthritis drug

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis…

biosimilar-disease-drug

FDA approves Novartis’ biosimilar to treat multiple inflammatory diseases

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis…

cimzia arthritis x-ray hands bones

Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab

Industry news / 1 August 2016 / Sanofi / Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis…

biosimilar-etanercept

FDA committee recommends approval of Sandoz’s biosimilar etanercept

Industry news / 14 July 2016 / Victoria White, Digital Content Producer

The Arthritis Advisory Committee voted unanimously in support of biosimilar etanercept for all five indications of the reference product…

certolizumab-pegol

NICE recommends certolizumab pegol in draft guidance

Industry news / 12 July 2016 / Victoria White, Digital Content Producer

Certolizumab pegol is recommended as an option for people with severe rheumatoid arthritis when other drugs haven’t worked or aren’t suitable…

rheumatoid arthritis

Rheumatoid arthritis testing market to hit $399.5m by 2022

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

The rheumatoid arthritis testing market is forecast to rise from $338.5 million in 2015 to $399.5 million by 2022, according to GlobalData…

baracitinib

New data for baricitinib in rheumatoid arthritis presented at EULAR

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

Findings from the RA-BEYOND study demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage…

Bristol-Myers Squibb shares significant new findings in rheumatoid arthritis research

Bristol-Myers Squibb shares significant new findings in rheumatoid arthritis research

Industry news / 8 June 2016 / Mandy Parrett, Editorial Assistant

Global biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.

Sirukumab

Sirukumab meets both co-primary endpoints in rheumatoid arthritis study

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis…

Sarilumab

sarilumab demonstrates superiority to adalimumab in rheumatoid arthritis

Industry news / 11 March 2016 / Victoria White

A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA…

Golimumab

Golimumab shows higher treatment persistence rates in patients with IMRD

Industry news / 16 February 2016 / Victoria White

A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.

sirukumab

Phase III study of sirukumab in giant cell arteritis starts

Industry news / 27 November 2015 / Victoria White

Sirukumab is an investigational human anti-IL-6 monoclonal antibody that selectively binds with high affinity to the IL-6 cytokine…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +